Partners of ANeuroTech

Olivier Wespe
Director Business Development
R&D Solutions


The Status of ANT01 and ANeuroTech

23 February 2022
FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD).

Read more

Scroll to Top